Skip to content
Lewis Lung Carcinoma Mouse Model
The Lewis Lung Carcinoma tumor model utilizes the LL/2 cell line due to its ability to closely mimic the tumor microenvironment and behavior of lung cancer, the leading cause of cancer-related deaths in the world. With a five-year survival rate of less the 20%, effective therapeutics are urgently needed, making the LL/2 tumor model ideal for preclinical non-small-cell lung cancer studies.
We have characterized the LL/2 mouse model expressed as a flank model in C57BL/6 mice for study of primary tumors and metastatic disease. Our model is easily adaptable to suit your therapeutic inquiries and downstream analyses.
Fast Growing and Reproducible
The fast-growing tumors in our LL/2 syngeneic model allow for efficient and reproducible analysis or therapeutic agents.
Metastatic Potential
The flank syngeneic LL/2 model produces tumors with high vascularization and can metastasize to organs and tissues such as the lungs, liver, pancreas, and lymph nodes.
Immune Response and Treatments
The LL/2 syngeneic mouse model provides an immune competent background to evaluate immune and toxicity responses to therapeutics agents.
LL/2 Mouse Model
LL/2 is a highly tumorigenic cell line with high vascularization of tumors and metastasis from the primary tumor site that can be investigated in a flank model.
Commonly Requested Endpoints
Histopathology
Our customizable histopathological analysis can help evaluate tumor microenvironments, track tumor progression and metastases and inform treatment decisions.
Flow Cytometry
Our flow cytometry expertise can help characterize tumor-infiltration T lymphocytes, identity immune biomarkers, and so much more.